Role of β1-3-adrenoceptors in blood pressure control at rest and during tyramine-induced norepinephrine release in spontaneously hypertensive rats

Hypertension

Volumn 55, Issue 5, 2010, Pages 1224-1230

  Berg, Torill ^a   Piercey, Bruce W ^a   Jensen, Jørgen ^b  

^a UNIVERSITY OF OSLO   (Norway)

^b NATIONAL INSTITUTE OF OCCUPATIONAL HEALTH   (Norway)

Author keywords

adrenoceptors; Adrenal glands; Blood pressure; Heart; Hypertension; Sympathetic nervous system; Total peripheral vascular resistance

Indexed keywords

1 (2 ETHYLPHENOXY) 3 (1,2,3,4 TETRAHYDRO 1 NAPHTHYLAMINO) 2 PROPANOL OXALATE; 3 ISOPROPYLAMINO 1 (7 METHYL 4 INDANYLOXY) 2 BUTANOL; 5 [2 [[2 HYDROXY 3 [4 (1 METHYL 4 TRIFLUOROMETHYL 2 IMIDAZOLYL)PHENOXY]PROPYL]AMINO]ETHOXY]SALICYLAMIDE; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR; NADOLOL; PROPRANOLOL; RESERPINE; TYRAMINE; CATECHOLAMINE; NORADRENALIN;

ADRENERGIC SYSTEM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; HYPERTENSION; MALE; NONHUMAN; NORADRENALIN RELEASE; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE HEART FAILURE RAT; VASOCONSTRICTION; VASODILATATION; ANIMAL; BLOOD; BLOOD PRESSURE; DRUG EFFECT; HEART OUTPUT; HEART RATE; HEART STROKE VOLUME; PHYSIOLOGY; REST; SECRETION; SPONTANEOUSLY HYPERTENSIVE RAT; VASCULAR RESISTANCE; WISTAR KYOTO RAT;

ANIMALS; BLOOD PRESSURE; CARDIAC OUTPUT; CATECHOLAMINES; HEART RATE; MALE; NOREPINEPHRINE; PROPRANOLOL; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RECEPTORS, ADRENERGIC, BETA-1; RECEPTORS, ADRENERGIC, BETA-2; RECEPTORS, ADRENERGIC, BETA-3; REST; STROKE VOLUME; TYRAMINE; VASCULAR RESISTANCE;

EID: 77951499098     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.109.149286     Document Type: Article

References (23)

1. Knaus AE, Muthig V, Schickinger S, Moura E, Beetz N, Gilsbach R, Hein L. d2-Adrenoceptor subtypes: unexpected functions for receptors and ligands derived from gene-targeted mouse models. Neurochem Int. 2007;515:277-281. (Pubitemid 47374320)
2. Werstiuk ES, Lee RM. Vascular/3-adrenoceptor function in hypertension and in ageing. Can J Physiol Pharmacol. 2000;786:433-452.
3. Queen LR, Ji Y, Xu B, Young L, Yao K, Wyatt AW, Rowlands DJ, Siow RC, Mann GE, Ferro A. Mechanisms underlying/32-adrenoceptor-mediated nitric oxide generation by human umbilical vein endothelial cells. J Physiol. 2006;576:585-594. (Pubitemid 44490147)
4. Gauthier C, Seze-Goismier C, Rozec B./33-adrenoceptors in the cardiovascular system. Clin Hemorheol Microcirc. 2007;37:193-204.
5. Rauls RA, Tan Y, Knuepfer MM. Central/3-adrenoceptors mediate phasic and sustained components of hemodynamic responses to acute behavioral stress. Brain Res. 2005;1048(1-2):98-107. (Pubitemid 40800264)
6. Starke K, Gothert M, Kilbinger H. Modulation of neurotransmitter release by presynaptic autoreceptors. Physiol Rev. 1989;693:864-989. (Pubitemid 19184852)
7. Rumantir MS, Jennings GL, Lambert GW, Kaye DM, Seals DR, Esler MD. The 'adrenaline hypothesis' of hypertension revisited: evidence for adrenaline release from the heart of patients with essential hypertension. J Hypertens. 2000;186:717-723.
8. Keeton TK, Campbell WB. The pharmacologic alteration of renin release. Pharmacol Rev. 1980;322:81-227.
9. Kubista H, Boehm S. Molecular mechanisms underlying the modulation of exocytotic noradrenaline release via presynaptic receptors. Pharmacol Ther. 2006;1121:213-242. (Pubitemid 44301493)
10. Berg T. Increased counteracting effect of eNOS and nNOS on an a1-adrenergic rise in total peripheral vascular resistance in spontaneous hypertensive rats. Cardiovasc Res. 2005;674:736-744. (Pubitemid 41033369)
11. Galitzky J, Reverte M, Portillo M, Carpene C, Lafontan M, Berlan M. Coexistence of/31-,/32-, and/33-adrenoceptors in dog fat cells and their differential activation by catecholamines. Am J Physiol. 1993;2643: E403-E412.
12. Westfall TC, Weston AH. Neurotransmission: the autonomic and somatic motor nervous systems. In: Brunton LL, Lazo JS, Parker KL, eds. Goodman Gilman's The Pharmacological Basis of Therapeutics. 11thed. New York, NY: McGraw-Hill; 2007.
13. Kneale BJ, Chowienczyk PJ, Brett SE, Coltart DJ, Ritter JM. Gender differences in sensitivity to adrenergic agonists of forearm resistance vasculature. J Am Coll Cardiol. 2000;364:1233-1238.
14. Jacobsen TN, Converse RL Jr, Victor RG. Contrasting effects of propranolol on sympathetic nerve activity and vascular resistance during orthostatic stress. Circulation. 1992;85:1072-1076.
15. Mallem MY, Toumaniantz G, Serpillon S, Gautier F, Gogny M, Desfontis JC, Gauthier C. Impairment of the low-affinity state/31-adrenoceptor-induced relaxation in spontaneously hypertensive rats. Br J Pharmacol. 2004;1435:599-605. (Pubitemid 39524277)
16. Bristow MR./3-Adrenergic receptor blockade in chronic heart failure. Circulation. 2000;1015:558-569. (Pubitemid 30080872)
17. Sterin-Borda L, Bernabeo G, Ganzinelli S, Joensen L, Borda E. Role of nitric oxide/cyclic GMP and cyclic AMP in/33 adrenoceptor-chronotropic response. J Mol Cell Cardiol. 2006;404:580-588.
18. Brede M, Nagy G, Philipp M, Sorensen JB, Lohse MJ, Hein L. Differential control of adrenal and sympathetic catecholamine release by d2-adrenoceptor subtypes. Mol Endocrinol. 2003;178:1640-1646. (Pubitemid 36930476)
19. Fung MM, Nguyen C, Mehtani P, Salem RM, Perez B, Thomas B, Das M, Schork NJ, Mahata SK, Ziegler MG, O'Connor DT. Genetic variation within adrenergic pathways determines in vivo effects of presynaptic stimulation in humans. Circulation. 2008;1174:517-525.
20. Vincent HH, Man in 't Veld AJ, Boomsma F, Derkx F, Schalekamp MA. Compound ICI 118,551, a/32-adrenoceptor antagonist, lowers blood pressure. J Hypertens Suppl. 1985;3:S247-S249.
21. Lund-Johansen P. Hemodynamic consequences of long-term/3-blocker therapy: a 5-year follow-up study of atenolol. J Cardiovasc Pharmacol. 1979;15:487-495. (Pubitemid 10189992)
22. Warmack TS, Estes MA, Heldenbrand S, Franks AM./3-Adrenergic antagonists in hypertension: a review of the evidence. Ann Pharmacother 2009;4312:2031-2043.
23. Dawes M, Chowienczyk PJ, Ritter JM. Effects of inhibition of the L-arginine/nitric oxide pathway on vasodilation caused by/3-adrenergic agonists in human forearm. Circulation. 1997;959:2293-2297. (Pubitemid 27191007)